Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1147103

registered interest
date	30/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	West Hertfordshire Hospitals NHS Trust: Capital Investment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much West Hertfordshire Hospitals NHS Trust has requested from his Department for capital building projects.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	292170
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>The Department does not hold information centrally on all submitted capital bids.</p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 08/10/2019 15:53:17 answering member 4362 label Biography information for Edward Argar
tabling member	1528 label Biography information for Sir Mike Penning

1128441

registered interest
date	23/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of evidence base on the cost-effectiveness of medical cannabis.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257705
answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:23:02 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1128443

registered interest
date	23/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the interim report produced by NHS England to identify the barriers that are blocking access to prescribed medicinal cannabis by patients.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257707
answer	answer is ministerial correction date of answer 07/06/2019 answer text <p>The NHS England process review is underway and interviews are scheduled to take place over June 2019. The interim report will not be published, as by its nature any findings will be incomplete. The Government is, however, committed to publishing a summary of the final findings and recommendations before summer recess.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257708 question first answered 07/06/2019 14:49:30 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1128444

registered interest
date	23/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the final report by NHS England to identify the barriers that are blocking access to prescribed medicinal cannabis by patients.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257708
answer	answer is ministerial correction date of answer 07/06/2019 answer text <p>The NHS England process review is underway and interviews are scheduled to take place over June 2019. The interim report will not be published, as by its nature any findings will be incomplete. The Government is, however, committed to publishing a summary of the final findings and recommendations before summer recess.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257707 question first answered 07/06/2019 14:49:30 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1128296

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which countries his Department is engaging with in order to learn from their experiences in getting patients access to medical cannabis.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257472
answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>In developing its policy on cannabis-based products for medicinal use, the Government looked at approaches taken by other countries to learn from their experience. Broadly two approaches have been taken: to regulate as a medicine (both licenced and unlicensed) as in the United Kingdom or to regulate outside of the medicinal regime as in Canada. In reviewing the available international evidence, the Chief Medical Officer for England and Chief Medical Adviser to the UK Government, looked at evidence reviews from the United States, Ireland, Australia, and the World Health Organization. Departmental officials have also reviewed information from a wide range of other countries and have spoken to the authorities and organisations in Australia, Canada, Denmark, the Netherlands, and the United States (New York).</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257473 question first answered 10/06/2019 13:28:33 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1128297

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what evidence his Department has reviewed from other countries on the effectiveness of cannabis as a medicine.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257473
answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>In developing its policy on cannabis-based products for medicinal use, the Government looked at approaches taken by other countries to learn from their experience. Broadly two approaches have been taken: to regulate as a medicine (both licenced and unlicensed) as in the United Kingdom or to regulate outside of the medicinal regime as in Canada. In reviewing the available international evidence, the Chief Medical Officer for England and Chief Medical Adviser to the UK Government, looked at evidence reviews from the United States, Ireland, Australia, and the World Health Organization. Departmental officials have also reviewed information from a wide range of other countries and have spoken to the authorities and organisations in Australia, Canada, Denmark, the Netherlands, and the United States (New York).</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257472 question first answered 10/06/2019 13:28:33 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1128298

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which groups of NHS staff will receive training from Health Education England.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257474
answer	answer is ministerial correction date of answer 07/06/2019 answer text <p>Health Education England has been commissioned to produce e-learning resources for clinicians and healthcare professionals to raise awareness of the regulation, guidance and evidence around cannabis-based products for medicinal use, and to build confidence in appropriate use and prescribing of such products. These resources will shortly be available and will be accessible by all healthcare professionals across the United Kingdom.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 07/06/2019 14:51:23 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1128299

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care on 20 May 2019, Official Report, column, 571, what plans he has to include observational trials in building up the existing evidence-base.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257475
answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>In all areas of scientific research, a range of evidence builds our understanding. This includes individual cases and observational trials. It is the promise shown from these observational studies and experience, from all around the world, that provides the basis for public funding of further research into the use of cannabis based products as medicines through the National Institute for Health Research. This further clinical research will provide a greater level of understanding of cannabis-based medicines, how to use them to best effect, who may benefit and under what circumstances, how cannabis interacts with other medications and define further any contraindications. It is this level of research outcomes that will provide confidence to prescribers and the information necessary to make routine funding decisions within the National Health Service.</p><p>The existing experience, studies and research in this area will be used by the National Institute for Health and Care Excellence to develop their clinical guidelines due to be published later this year.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:26:43 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1128300

registered interest
date	22/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the cost-effectiveness of patients receiving an NHS prescription for wholeplant medical cannabis.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	257476
answer	answer is ministerial correction date of answer 10/06/2019 answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 257706 question first answered 10/06/2019 13:18:03 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1127082

registered interest
date	16/05/2019
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Motorways: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, how many extra emergency refuge areas have been added to existing stretches of all lane running motorways.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	255305
answer	answer is ministerial correction date of answer 23/05/2019 answer text <p>Reviews of the first two schemes to be designed to the all lane running standard, both on the M25, shows they are performing well and in line with expectations; successfully increasing capacity and improving journeys for motorists. These reviews found that the M25 schemes delivered an overall 27% safety improvement.</p><p> </p><p>Nevertheless, to help drivers feel more confident they can find a place to stop in an emergency, Highways England have committed to reducing the maximum spacing of emergency areas which is currently about every mile and a half (about 90 seconds at 60mph), to around every mile (about every minute at 60mph). This will take place on new schemes being constructed from 2020 onwards.</p><p> </p><p>Currently the average spacing on all lane running sections is just over a mile.</p><p> </p><p>In addition, in the next twelve months construction work will commence to install 10 additional emergency refuge areas on the M25.</p> answering member constituency Hereford and South Herefordshire answering member printed Jesse Norman question first answered 23/05/2019 10:41:58 answering member 3991 label Biography information for Jesse Norman
tabling member	1528 label Biography information for Sir Mike Penning